Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024, 74(3):229–263.

Siegel RL, Miller KD, Wagle NS, Jemal A: Cancer statistics, 2023. CA: A Cancer Journal for Clinicians 2023, 73(1):17–48.

Team TNLSTR: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine 2011, 365(5):395–409.

Moyer VA: Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2014, 160(5):330–338.

Wender R, Fontham ETH, Barrera E, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Scott Gazelle G, Kelsey DK et al: American Cancer Society lung cancer screening guidelines. CA: A Cancer Journal for Clinicians 2013, 63(2):106–117.

Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M et al (2021) Screening for Lung Cancer. JAMA 325(10):962

Article  PubMed  Google Scholar 

Wolf AMD, Oeffinger KC, Shih TYC, Walter LC, Church TR, Fontham ETH, Elkin EB, Etzioni RD, Guerra CE, Perkins RB et al: Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians 2024, 74(1):50–81.

Kerpel-Fronius A, Tammemägi M, Cavic M, Henschke C, Jiang L, Kazerooni E, Lee C-T, Ventura L, Yang D, Lam S et al (2022) Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. J Thorac Oncol 17(1):56–66

Article  PubMed  Google Scholar 

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V et al (2016) The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11(1):39–51

Article  PubMed  Google Scholar 

Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J, Kernstine KH et al (2024) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 19(7):1007–1027

Article  PubMed  Google Scholar 

Odintsov I, Sholl LM (2024) Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology 56(2):192–204

Article  CAS  PubMed  Google Scholar 

Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, Bonanno L (2024) The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol 196:104295

Article  PubMed  Google Scholar 

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet 398(10308):1344–1357

Article  CAS  Google Scholar 

Felip E, Altorki N, Zhou C, Vallières E, Martínez-Martí A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M et al (2023) Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol 34(10):907–919

Article  CAS  PubMed  Google Scholar 

O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M et al (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23(10):1274–1286

Article  PubMed  Google Scholar 

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ et al (2022) Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 386(21):1973–1985

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooms C, Majem M, Eigendorff E et al (2023) Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. N Engl J Med 389(6):491–503

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S et al (2023) Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. N Engl J Med 389(18):1672–1684

Article  CAS  PubMed  Google Scholar 

Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L et al (2024) Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med 390(19):1756–1769

Article  CAS  PubMed  Google Scholar 

Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, Xing W, Chen Q, Yang L, Mei J et al (2024) Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer. JAMA 331(3):201

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X et al (2022) Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J Clin Oncol 40(12):1301–1311

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, De Wit M et al (2017) Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 377(20):1919–1929

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al (2021) Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. J Clin Oncol 39(21):2339–2349

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK et al (2023) Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 41(11):1986–1991

Article  PubMed  Google Scholar 

Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O et al (2021) Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. The Lancet 397(10274):592–604

Article  CAS  Google Scholar 

Herbst RS, Giaccone G, De Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S et al (2020) Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N Engl J Med 383(14):1328–1339

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Lee J-S, Ciuleanu T-E, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A et al (2023) Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol 41(6):1200–1212

Article  CAS  PubMed  Google Scholar 

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N et al (2023) Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 41(11):1992–1998

Article  CAS  PubMed  PubMed Central  Google Scholar 

Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA et al (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol 16(11):1909–1924

Article  CAS  PubMed  Google Scholar 

Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH et al (2023) Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 41(11):1999–2006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Ciuleanu T-E, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J et al (2024) Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer 211:114296

Article  CAS  PubMed  Google Scholar 

Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE (2021) Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA. Future Oncol 17(31):4045–4055

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su W-C et al (2023) Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC. N Engl J Med 389(2):137–147